enquiry@goldsteinresearch.com
We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. | × |
---|
Understand the COVID-19 Outbreak and its impact on global & regional businesses
request free proposal
Insights on a world turned upside down : Re-imagining
The post-COVID19 Business resilience & recovery
How effective strategies and business recovery plans are winning the race
request free proposal
Goldstein Market Intelligence help you navigate through the COVID-19 crisis,
we will provide you most relevant market insights on crisis management,
recovery strategy & business continuity.
2020-09-01
710
India
India supplies 20% of global generic medicines market exports, in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years. Epidemiological factors like 20% increase in the patient pool, new diseases, and lifestyle and increasing prevalence of lifestyle diseases will boost the demand for pharmaceuticals in India.
Goldstein Research analyst forecast the India pharmaceuticals market size is set to grow at a CAGR of 15.9% over the forecast years of 2017-2030.
On the basis of type, API’s hold the largest market segment as India has become the third largest global generic API merchant market by 2016, with a 7.2 percent market share and The Indian pharmaceutical industry accounts for the second largest number of Abbreviated New Drug Applications (ANDAs), is the world’s leader in Drug Master Files (DMFs) applications with the US.
According to our global market study on the basis of extensive primary and secondary research: “One trend is that most players are using inorganic growth as a key growth strategy. More deals will happen in Indian companies acquiring assets in US/Europe, rather than MNCs acquiring Indian companies”
According to the report, major driving factor for India pharmaceutical industry is the diversified portfolio that accounts for over 10% of global pharmaceutical production. Over 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different APIs 35.7% of all drug master filings from India is registered in the USA in 2015.
Further, the report states that the major challenge is that currently, the industry is dominated by thousands of small, medium and large players. Most players will not be able to address quality and regulatory issues adequately and therefore, going forward, the industry will have a bimodal distribution.
Based on players, highest expenditure based on research and development is done by Sun Pharma (USD 352 Million), followed by Dr. Reddy (USD 199 million). Cipla formed an exclusive partnership with Serum Institute of India to sell vaccines in South Africa. Dr. Reddy’s accounted for the largest share in the Indian pharma market, with sales of USD 2.2 billion in 2016 and Lupin being the second largest with sales of USD 2.09 billion in 2016 in Indian Pharma Market.
The report covers the present ground scenario and the future growth prospects of India Pharmaceuticals Market for 2017-2030 and statistics of Branded and Generic Drugs along with the details of ongoing projects in pharma sector in India. We calculated the market size and revenue share on the basis of revenue generated from major players across the globe.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
India Pharmaceuticals Market Outlook 2017-2030, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the India pharmaceuticals market. The report also includes Porter's five force model, SWOT analysis, company profiling, business strategies of market players and their business models. India Pharmaceutical market report also recognizes value chain analysis to understand the cost differentiation to provide a competitive advantage to the existing and new entry players.
Impact of COVID-19 Outbreak on “India Pharmaceutical Market ”, Manufacturers, Contract Manufacturers Suppliers and Recovery Strategy. A complete detailed chapter of 50-70 pages which includes the data and information focused on impacts of the pandemic on the India Pharmaceutical Market . It also showcases the expected recovery schedule and losses in the industry and other various major factors.
Our India Pharmaceutical market report comprises of the following companies as the key players in the market:
For a full detailed overview, send us the sample request.
We can provide two-hour complimentary interaction with our analyst after the purchase of this market report. Details are imparted within the report.
A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements
OR Call Us:+1-646-568-7747Global Point of Care Testing (POCT) Devices Market Outlook: Market Segmentation By Systems Basis, By Clinical Specialties & Diseases, By Areas of Use, By End User & by Region With COVID-19 impact & Forecast 2017-2030
Global Home Healthcare Equipment Market Size , Share, By Device, By Distribution Channel, By End User With COVID-19 impact & Forecast 2017-2030
Global Connected Healthcare Market Analysis by type, by function(Home/Remote Monitoring, Clinical Monitoring) & by application with regional outlook and forecast to 2030
India In-Vitro Diagnostics (IVD) Market Outlook 2030: Based on Healthcare Segments, Based on Application, Based on End User With COVID-19 impact & Forecast 2017-2030
Global Connected Medical Device Market Outlook 2030: Based on Product Type, By Devices, Based on Application, By End-User, Based on Geography With COVID-19 impact & Forecast 2017-2030